14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
×
Home
/
Stock Analysis
/
Compare Terminal
/
ENTX vs LEXX
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
ENTX vs LEXX: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
ENTX Wins Head-to-Head Institutional Verdict (3–2 across 6 Pillars · 6–1 Matrix Metrics)
ENTX Overall Winner
6-Pillar Tally: ENTX 3 – 2 LEXX (1 Tie)
Matrix Metrics: ENTX 6 – 1 LEXX
As of Nov 16, 2026, Entera Bio Ltd. (ENTX) is the stronger overall head-to-head candidate over Lexaria Bioscience Corp. (LEXX) in the Tradestie Institutional Equity Comparison Engine, winning 6–1 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow, Options & Positioning). ENTX carries a Unified Composite Score of 53.9/100 (HOLD) at $3.02 (N/M Forward P/E, 0.0% operating margin), whereas LEXX carries 33.3/100 (SELL) at $4.41 (N/M Forward P/E, -3862.9% operating margin).
ENTX
NASDAQ
Head-to-Head Winner
Entera Bio Ltd. Ordinary Shares
Biological Products, (No Disgnostic Substances)
Market Cap
$541.6M
TTM Revenue
N/A
Forward P/E
N/M
Beta / 30D Vol
1.07β · 46% Vol
Unified Composite Score
53.9 / 100
HOLD
Tech 37.0
Fund 54.0
Flow 72.0
Mom 60.0
Weinstein Technical Phase
Neutral · Hold
Mixed signals - no dominant trend phase, RSI 50
RSI-14: 49.5 · SMA20: $3.09 · SMA50: $2.90
LEXX
NASDAQ
Lexaria Bioscience Corp. Common Stock
Pharmaceutical Preparations
Market Cap
$9.4M
TTM Revenue
$194,000
Forward P/E
N/M
Beta / 30D Vol
11.09β · 92% Vol
Unified Composite Score
33.3 / 100
SELL
Tech 50.0
Fund 30.0
Flow 50.0
Mom 50.0
Weinstein Technical Phase
Neutral · Hold
Mixed signals - no dominant trend phase, RSI 58
RSI-14: 58.0 · SMA20: $3.78 · SMA50: $3.62
6-Pillar Scorecard Institutional Category Breakdown (ENTX 3 – 2 LEXX)
Columns: Metric · ENTX · LEXX
1. Valuation Multiples
LEXX
Forward P/E
N/M
N/M
Trailing P/E
N/M
N/M
PEG Ratio
N/M
N/M
EV / Revenue
N/M
30.7x
2. Growth & Scale
LEXX
Revenue Growth (YoY)
-100.0%
-88.5%
Earnings Growth (YoY)
+0.0%
+0.0%
TTM Revenue (USD)
N/A
$194,000
Market Cap
$541.6M
$9.4M
3. Profitability & Quality
ENTX
Gross Margin
N/A
100.0%
Operating Margin
0.0%
-3862.9%
Net Profit Margin
0.0%
0.0%
Return on Equity (ROE)
-20.3%
-162.8%
4. Balance Sheet & Cash Flow
ENTX
Cash Generation (TTM)
-$16M
-$7.5M
Cash Flow Margin
N/A
N/A
Net Cash / Leverage
$265M Net Cash
$3.4M Net Cash
Dividend Yield
None (0.00%)
None (0.00%)
5. Options & Positioning
ENTX
Options Structure Phase
CONSOLIDATION
UNCLASSIFIED
Current IV / %ile
113.8% (32nd %ile)
N/A (N/A)
Put/Call OI Skew
N/A
N/A
OBV Trend / Tech Phase
NEUTRAL · Neutral
NEUTRAL · Neutral
6. R&D & Supply-Chain Moat
Tie
OpEx & R&D Intensity
N/A
N/A
90D R&D Disclosures
0 papers
0 papers
Competitive Moat
Cyclical / Execution-Driven Positioning
Cyclical / Execution-Driven Positioning
Supply-Chain Role
Biotechnology Operator
Biotechnology Operator
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: ENTX (6) vs LEXX (1)
Institutional Metric
ENTX
LEXX
Criterion
Row Edge
Market Capitalization
Scale
$541.6M
$9.4M
Larger Scale
ENTX
Trailing P/E Ratio
Valuation
N/M
N/M
Lower Multiple
Tie
Forward P/E Ratio
Valuation
N/M
N/M
Lower Multiple
Tie
Revenue Growth (YoY)
Growth
-100.0%
-88.5%
Higher Growth
LEXX
Operating Margin (TTM)
Profitability
0.0%
-3862.9%
Higher Margin
ENTX
Net Profit Margin
Profitability
0.0%
0.0%
Higher Margin
Tie
Return on Equity (ROE)
Capital Efficiency
-20.3%
-162.8%
Higher ROE
ENTX
52-Week Range Position
Momentum
64% ($1–$4)
29% ($0–$14)
Stronger Trend
ENTX
Beta / 30D Volatility
Risk Regime
1.07β · 46% Vol
11.09β · 92% Vol
Lower Realized Risk
ENTX
Unified Institutional Score
Composite Signal
53.9 / 100 (HOLD)
33.3 / 100 (SELL)
Higher Composite
ENTX
Trailing 12M Revenue (USD)
Operating Scale
N/A
$194,000
FX-Normalized USD
Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A
100.0%
Higher Margin
Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev
N/M PEG · 30.7x EV/Rev
Lower Multiple
Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$16M ($265M Net Cash)
-$7.5M ($3.4M Net Cash)
Higher Cash / Net Cash
Solvency
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M
3M
6M
1Y
1M Horizon
LEXX +41.51 pp
ENTX:
+12.69%
·
LEXX:
+54.2%
3M Horizon
ENTX +66.22 pp
ENTX:
+4.5%
·
LEXX:
-61.72%
6M Horizon
LEXX +541.83 pp
ENTX:
+145.53%
·
LEXX:
+687.36%
1Y Horizon
LEXX +290.69 pp
ENTX:
+10.22%
·
LEXX:
+300.91%
Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
Split-Invariant USD Revenue & Operating Margin (%)
Period
ENTX Revenue
LEXX Revenue
ENTX Op. Margin
LEXX Op. Margin
Margin Leader
FY2018
N/A
$0M
N/A
-1525.4%
LEXX
FY2019
N/A
$0M
N/A
-1868.0%
LEXX
FY2020
$0M
$0M
-3059.7%
-1062.2%
LEXX
FY2021
$0M
$0M
-2139.6%
-786.8%
LEXX
FY2022
$0M
$0M
-9714.2%
-2591.7%
LEXX
FY2023
N/A
$0M
N/A
-2888.5%
LEXX
FY2024
$0M
$0M
-5295.6%
-1239.2%
LEXX
FY2025
$0M
$0M
-27450.0%
-1683.0%
LEXX
ENTX
CONSOLIDATION
79d in phase · OBV NEUTRAL
Current IV
113.8%
IV Percentile
32nd %ile
Put/Call OI Skew
N/A
IV Regime
Balanced (25th–60th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BULLISH
OBV Flow
NEUTRAL
LEXX
UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV
N/A
IV Percentile
N/A
Put/Call OI Skew
N/A
IV Regime
Unclassified
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
NEUTRAL
OBV Flow
NEUTRAL
ENTX Moat Profile
Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $541.6M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
LEXX Moat Profile
Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $9.4M market capitalization and -3862.9% operating margin.
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
Investor FAQ ENTX vs LEXX Key Questions & Quantitative Answers
Is ENTX or LEXX a better stock to buy right now?
As of Nov 16, 2026, Entera Bio Ltd. (ENTX) is the stronger overall head-to-head candidate over Lexaria Bioscience Corp. (LEXX) in the Tradestie Institutional Equity Comparison Engine, winning 6–1 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow, Options & Positioning). ENTX carries a Unified Composite Score of 53.9/100 (HOLD) at $3.02 (N/M Forward P/E, 0.0% operating margin), whereas LEXX carries 33.3/100 (SELL) at $4.41 (N/M Forward P/E, -3862.9% operating margin). Technically, ENTX sits in a Neutral phase (RSI 49.5, CONSOLIDATION options structure) and LEXX sits in a Neutral phase (RSI 58.0, UNCLASSIFIED options structure).
Does ENTX or LEXX have stronger revenue and earnings growth?
LEXX leads the Growth & Scale pillar: ENTX posts -100.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with LEXX at -88.5% YoY revenue growth and +0.0% YoY earnings growth on $194,000 TTM revenue (100.0% gross margin, -3862.9% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), ENTX cumulative revenue shifted N/A while LEXX shifted N/A. In operating R&D and SG&A reinvestment, ENTX deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for LEXX.
Is ENTX or LEXX cheaper on valuation?
LEXX screens cheaper on headline valuation multiples. ENTX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas LEXX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 30.7x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ENTX (-20.3% ROE) versus LEXX (-162.8% ROE) capital efficiency.
How is options market volatility positioned on ENTX vs LEXX?
In options market volatility and institutional positioning, ENTX carries 113.8% implied volatility (32nd %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (1.07β · 46% Vol realized risk). By comparison, LEXX carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (11.09β · 92% Vol realized risk).
Entera Bio Ltd. Ordinary Shares (ENTX) Research Suite
Lexaria Bioscience Corp. Common Stock (LEXX) Research Suite
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.